60 research outputs found
Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial
<p>Abstract</p> <p>Background</p> <p>Increasing evidence suggests the bidirectional interplay between parathyroid hormone and aldosterone as an important mechanism behind the increased risk of cardiovascular damage and bone disease observed in primary hyperparathyroidism. Our primary object is to assess the efficacy of the mineralocorticoid receptor-blocker eplerenone to reduce parathyroid hormone secretion in patients with parathyroid hormone excess.</p> <p>Methods/design</p> <p>Overall, 110 adult male and female patients with primary hyperparathyroidism will be randomly assigned to eplerenone (25 mg once daily for 4 weeks and 4 weeks with 50 mg once daily after dose titration] or placebo, over eight weeks. Each participant will undergo detailed clinical assessment, including anthropometric evaluation, 24-h ambulatory arterial blood pressure monitoring, echocardiography, kidney function and detailed laboratory determination of biomarkers of bone metabolism and cardiovascular disease.</p> <p>The study comprises the following exploratory endpoints: mean change from baseline to week eight in (1) parathyroid hormone(1â84) as the primary endpoint and (2) 24-h systolic and diastolic ambulatory blood pressure levels, NT-pro-BNP, biomarkers of bone metabolism, 24-h urinary protein/albumin excretion and echocardiographic parameters reflecting systolic and diastolic function as well as cardiac dimensions, as secondary endpoints.</p> <p>Discussion</p> <p>In view of the reciprocal interaction between aldosterone and parathyroid hormone and the potentially ensuing target organ damage, the EPATH trial is designed to determine whether eplerenone, compared to placebo, will effectively impact on parathyroid hormone secretion and improve cardiovascular, renal and bone health in patients with primary hyperparathyroidism.</p> <p>Trial registration</p> <p>ISRCTN33941607</p
Speckle tracking echocardiography in patients with septic shock: a case control study (SPECKSS)
Early-stage heart failure with preserved ejection fraction in the pig: a cardiovascular magnetic resonance study
Association of Comorbidity Burden With Abnormal Cardiac Mechanics: Findings From the HyperGEN Study
Erratum: Impaired systolic function by strain imaging in heart failure with preserved ejection fraction ( Journal of the American College of Cardiology (2014) 63 (447-456))
Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
Background - Heart failure with preserved ejection fraction is associated with substantial morbidity and mortality, but effective treatments are lacking. We assessed the efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI), in patients with this disorder.
Methods - PARAMOUNT was a phase 2, randomised, parallel-group, double-blind multicentre trial in patients with New York Heart Association (NYHA) class IIâIII heart failure, left ventricular ejection fraction 45% or higher, and NT-proBNP greater than 400 pg/mL. Participants were randomly assigned (1:1) by central interactive voice response system to LCZ696 titrated to 200 mg twice daily or valsartan titrated to 160 mg twice daily, and treated for 36 weeks. Investigators and participants were masked to treatment assignment. The primary endpoint was change in NT-proBNP, a marker of left ventricular wall stress, from baseline to 12 weeks; analysis included all patients randomly assigned to treatment groups who had a baseline and at least one postbaseline assessment. This trial is registered at Clinicaltrials.gov, number NCT00887588.
Findings - 149 patients were randomly assigned to LCZ696 and 152 to valsartan; 134 in the LCZ696 group and 132 in the valsartan group were included in analysis of the primary endpoint. NT-proBNP was significantly reduced at 12 weeks in the LCZ696 group compared with the valsartan group (LCZ696: baseline, 783 pg/mL [95% CI 670â914], 12 weeks, 605 pg/mL [512â714]; valsartan: baseline, 862 pg/mL [733â1012], 12 weeks, 835 [710â981]; ratio LCZ696/valsartan, 0·77, 95% CI 0·64â0·92, p=0·005). LCZ696 was well tolerated with adverse effects similar to those of valsartan; 22 patients (15%) on LCZ696 and 30 (20%) on valsartan had one or more serious adverse event.
Interpretation - In patients with heart failure with preserved ejection fraction, LCZ696 reduced NT-proBNP to a greater extent than did valsartan at 12 weeks and was well tolerated. Whether these effects would translate into improved outcomes needs to be tested prospectively
Functional Strain-line Pattern in the Human Left Ventricle.
Analysis of deformations in terms of principal directions appears well suited for biological tissues that
present an underlying anatomical structure of \ufb01ber arrangement. We applied this concept here to study
deformation of the beating heart in vivo analyzing 30 subjects that underwent accurate three-dimensional
echocardiographic recording of the left ventricle. Results show that strain develops predominantly along
the principal direction with a much smaller transversal strain, indicating an underlying anisotropic, onedimensional contractile activity. The strain-line pattern closely resembles the helical anatomical structure
of the heart muscle. These \ufb01ndings demonstrate that cardiac contraction occurs along spatially variable
paths and suggest a potential clinical signi\ufb01cance of the principal strain concept for the assessment of
mechanical cardiac function. The same concept can help in characterizing the relation between functional
and anatomical properties of biological tissues, as well as \ufb01ber-reinforced engineered materials
- âŠ